menopause

A little exercise better than none for overweight postmenopausal women
A little exercise better than none for overweight postmenopausal womenWomen should not feel that they need to log long hours of vigorous exercise to see any benefits, says a study from Spain.
FDA approves drug for postmenopausal symptomsThe first drug combining estrogens with bazedoxifene has been approved by the U.S. Food and Drug Administration (FDA) for treatment of moderate-to-severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis.
New molecular entityOn February 26, 2013, FDA approved ospemifene (Osphena, Shionogi Inc.) for the treatment of moderate-to-severe dyspareunia resulting from vulvar and vaginal atrophy associated with menopause. Estrogen levels decline during menopause, resulting in a thinning and drying of vaginal tissues. This atrophy can cause a woman to experience pain during intercourse (dyspareunia).
NAMS updates recommendations for vulvovaginal atrophyEstrogen therapy is still the mainstay of therapy for moderate-to-severe symptoms and long-term studies on endometrial safety of local estrogen and ospemifene are lacking. Those are the key conclusions from an updated position statement on management of symptomatic vulvovaginal atrophy (VVA) in postmenopausal women issued by the North American Menopause Society (NAMS).
FDA approves first nonhormonal treatment for hot flashesFDA has approved low-dose paroxetine capsules (Brisdelle, Noven Pharmaceuticals), 7.5 mg/day, for treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause, also referred to as hot flashes and night sweats.
FDA approves first nonhormonal treatment for hot flashes associated with menopauseFDA has approved low-dose paroxetine capsules (Brisdelle, Noven Pharmaceuticals), 7.5 mg/day, for the treatment of moderate to severe vasomotor symptoms associated with menopause, also referred to as hot flashes and night sweats.
FDA approves first nonhormonal treatment for hot flashes associated with menopauseFDA has approved low-dose paroxetine capsules (Brisdelle, Noven Pharmaceuticals), 7.5 mg/day, for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause, also referred to as hot flashes and night sweats.
Clearing up HRT confusionThe British Menopause Society (BMS) on May 23 released updated recommendations on hormone replacement therapy (HRT), claiming that they are finally providing clarity to this murky issue. The new guidelines appear in the society’s flagship journal, Menopause International. Developed by a panel of experts, the guidelines discuss how women can optimize their menopause transition, focusing in particular on lifestyle and diet and the pros and cons of complementary therapies.
Are menopausal women more anxious?A new analysis from the SWAN study shows that anxiety before menopause does not correlate with anxiety during the menopausal transition. Researchers from the multisite Study of Women’s Health Across the Nation, report in Menopause that women who are calmer at premenopause actually are more susceptible to high anxiety during and after menopause than before menopause, and vice versa.
Pinpointing the final menstrual periodA study appearing in the Journal of Clinical Endocrinology & Metabolism (JCEM) April 2013 issue details a model to help predict when a women will experience her final menstrual period (FMP).